Menu Search
Equities

Biotage AB

BIOT:STO

Biotage AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)151.90
  • Today's Change-3.60 / -2.32%
  • Shares traded3.07k
  • 1 Year change+18.58%
  • Beta1.2863
Data delayed at least 15 minutes, as of Nov 26 2024 08:57 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Biotage AB had net income fall -8.21% from 268.00m to 246.00m despite a 19.54% increase in revenues from 1.57bn to 1.87bn.
Gross margin62.67%
Net profit margin12.08%
Operating margin16.50%
Return on assets5.21%
Return on equity6.85%
Return on investment6.05%
More ▼

Cash flow in SEKView more

In 2023, Biotage AB increased its cash reserves by 34.69%, or 153.00m. The company earned 284.00m from its operations for a Cash Flow Margin of 15.17%. In addition the company generated 35.00m cash from investing, though they paid out 142.00m more in financing than they received.
Cash flow per share5.47
Price/Cash flow per share28.23
Book value per share47.60
Tangible book value per share6.86
More ▼

Balance sheet in SEKView more

Biotage AB has a Debt to Total Capital ratio of 6.16%, a higher figure than the previous year's 5.99%.
Current ratio1.91
Quick ratio1.15
Total debt/total equity0.0656
Total debt/total capital0.0616
More ▼

Growth rates in SEK

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -17.90%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)0.74%
Div growth rate (5 year)1.30%
Payout ratio (TTM)49.81%
EPS growth(5 years)5.12
EPS (TTM) vs
TTM 1 year ago		17.55
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.